Kleresca®

CHANGING DERMATOLOGY THROUGH FLUORESCENT LIGHT ENERGY (FLE)

Learn more about the technology behind Kleresca®

Innovative technology using fluorescent light energy (FLE)

The Kleresca® platform offers non-invasive treatments for both therapeutic and aesthetic conditions using fluorescent light energy (FLE) to stimulate the skin's own biological processes and repair mechanisms through photobiomodulation (PBM)[5,25]. Demonstrating high safety and efficacy, our technology triggers documented skin repairing benefits for a number of diseases and conditions[5-9,19,20,27,28].

The importance of light

Light is present in our daily life in many processes, like helping us to synthesise vitamin D or allowing us to see colours. Light is also used in many medical treatments, including dermatology, wound healing, and pain relief. In order for the light to have a biological effect, it must be absorbed by cells and tissues. The following image shows a representation of the light spectrum with special emphasis on the visible light.



The skin is able to absorb visible light (from 400 to 700 nm) which may trigger a biological effect. Visible light will penetrate the skin in different ways depending on its wavelength.

Shorter wavelengths (blue colour) will penetrate only the most superficial parts of the skin (epidermis) whereas longer wavelengths (green, orange, red colour) will penetrate deeper into the tissue.

Depending on the depth reached in the skin, the different wavelengths of light can get access to a variety of biological structures and have different effects[1-5].



Transforming the skin from within

Fluorescent light energy (FLE) starts the photobiomodulation process in the skin. This is based on the evidence that photons are able to interact with biological systems, cells and tissues, which consequently induce molecular pathways, modulating several aspects of cell biology[1].

The physiological and therapeutic effects of FLE have recently been explored in several tissues and cells[32]. While the complete cellular and molecular mechanisms are not fully clarified, it is believed to largely affect cellular metabolism, increase adenosine triphosphate (ATP) and modulate reactive oxygen species (ROS). A change in ROS is known to affect transcription factors, responsible for growth, inflammation, cellular proliferation and oxygenation, eventually culminating in augmented tissue repair[33].

The clinical and biological documented effects of FLE include[2]:

- Anti-inflammatory response, especially beneficial for such conditions as acne, rosacea and keratosis pilaris
- Post-interventional inflammation and erythema (e.g. following IPL or laser treatments)
- Increased normalised cell growth for wound healing
- Photorejuvenation
- Scar prevention and recovery
- Increased angiogenesis

More spefically, red and orange light have been shown to induce the dissociation of nitric oxide from the enzyme cytochrome C oxidase, and have been associated with collagen regulation. Yellow light is generally believed to alter ATP production and fibroblast activity. Blue light specifically causes disruption of the endogenous *C. acnes* (formerly *P. acnes*), and green and blue light are also believed to be anti-inflammatory through a shift in cytokine production[1-3]. In addition to these general effects, the various wavelengths are known to penetrate different depths of the skin, gaining access to a variety of biological elements in the skin[2,4].



Graphical representation of fluorescent light energy (FLE) penetrating the different layers of the skin

The difference is fluorescent

The Kleresca® technology is based on fluorescent light energy (FLE) produced by excited light-absorbing chromophores when illuminated with a multi LED lamp.

The photo conversion of the gel leads to the production of a dynamic hyper-pulsed multi-wavelength spectrum of fluorescent light energy through the phenomenon of Stokes Shift[27].

These wavelengths have the capacity to penetrate to various depths of the skin and to stimulate the skin tissues and cells[5].

It appears that this hyperfast pulsing of light is the key to the technology's various benefits, like enhancing collagen production and anti-inflammatory effects.

In scientific studies, FLE has shown better outcomes on the treated cells than continuous conventional LED light[5]. Theories for enhanced collagen production with FLE suggest cytochrome C activation increasing mitochondrial energy production leading to downstream activation of various genes for collagen synthesis[1].

FLE has also been reported to activate nuclear factor kappa-light-chain-enhancer of activated B cell (NF-kB) – the master regulator of inflammation in normal quiescent cells[5].



The photoconverter gel absorbs blue light from Kleresca® Light



The chromophores convert the blue light into fluorescent light energy (FLE)



FLE stimulates the skin at the cellular level

Kleresca® FLE treatments

Kleresca® FLE treatments are based on photoconverter gels, which are non-absorbing formulations containing light absorbing molecules (chromophores)[27].

A thin layer of the photoconverter gel is topically applied on the targeted skin area, and subsequently illuminated with the Kleresca® Light, to create a biophotonic action in which fluorescent light energy (FLE) is generated[27].

Afterwards, the exhausted photoconverter gel is fully removed and the skin is cleaned and moisturised[25].

Together, the photoconverter gel and the Kleresca® Light source provides a unique and dynamic FLE output, both in terms of wavelength and energy delivered over a pre-defined treatment cycle time of 9 min[5].

No UV light or infrared light is emitted or generated. The FLE spectral output generated ranges from 500 to 650 nm, converting the blue light into green, yellow, orange and red wavelengths of the visible spectrum.

The Kleresca® FLE technology has been shown to modulate both disease affected and healthy skin, decreasing inflammation and enhancing the skin's overall texture[5-9,19,20,27,28].

Easy and pleasant treatment all year round

As this treatment causes no photosensitivity, it is suitable all year round including summer[9,19,20,27,28]. Patients typically describe the three-step treatment as a pleasant experience. It only takes 9 minutes under the lamp. With little to no-downtime, make-up can be applied immediately after the session[5-9,19,20,27,28].

The skin is cleaned and the Kleresca® Gel is applied.

Illuminated for 9 minutes under the Kleresca® Light, the gel converts the blue light into fluorescent light energy (FLE) that stimulates the skin's own repair mechanisms"

The gel is removed and the skin is cleaned and moisturised.

Treatment of acne

A variety of oral, topical, laser and light treatments have been reported to be effective against acne, although some may pose a range of challenges, like poor tolerability and side effects[3,6].

The Kleresca® FLE technology provides a unique multi-action treatment, targeting at the same time the bacteria responsible for acne (*C. acnes*), reducing inflammation, normalising cell activity and increasing the build-up of collagen, which reduces the signs of scarring[5-7,27].

Kleresca® Acne Treatment is the only alternative in the market that uses fluorescent light energy (FLE) and is able to treat active acne and acne scarring at the same time[5-9,27]. A gentle, non-systemic and painless technology that provides high efficacy, safety and results that are seen to last up to a year or above. 9 out of 10 acne patients experience noticeable improvements of their skin[5,6]. The treatment not only normalizes the skin but enables it to improve over time, even after the actual treatment has ended[5-7,27].





Before



After

Before



After

Treatment of rosacea

Common treatments of rosacea include topical, oral as well as light-based treatments[26].

Whereas most of the treatments for rosacea aim to combat discrete symptoms of the skin condition, either the vascular effect, the erythema, or the inflammation, not many treatments exist, which seem to influence the various factors involved in the occurrence of rosacea.

With the increasing knowledge of FLE[1,18,21,23,25], its benefits are becoming more widely documented. These include normalisation of the skin, reduction of inflammation and also stimulation of cells to activate the healing mechanisms that lead to a repairing response of the skin[1,18,21,23,25].

The anti-inflammatory properties and healing response stimulated by FLE have been well documented clinically in both inflammatory lesions of acne vulgaris[6] and in treatment of chronic wounds[22].

These observations support the pathophysiology related to rosacea.

In addition FLE has been documented to improve microvascularisation, inducing angiogenesis[5]. The ability of FLE to induce healthy vasculature and a normalised de-stressed environment in the skin is beneficial when treating rosacea, in that it improves blood distribution through enhanced lateral blood flow attenuating erythema and blushing.

FLE has proven to have fast results in rosacea patients, treating redness, flushing and pimples and eliminating burning and stinging sesations[19,20].



Before



After



Before



After

Skin rejuvenation

Many different treatment modalities exist to counteract the effects of cutaneous ageing. Ablative methods have been the mainstay for non-surgical facial rejuvenation. In recent years, non-ablative techniques have been developed with the aim of achieving facial rejuvenation without epidermal damage[16]. Photo rejuvenation is a novel non-ablative, non-thermal and atraumatic technique that induces collagen synthesis through photobiomodulation (PBM)[1,17].

Studies with the Kleresca® FLE technology have shown to stimulate the skin's own rejuvenation process. The treatment slows down the signs of skin aging by inducing collagen production up to 400%. This improves pore size, fine lines and overall skin texture, leaving the skin revitalised, firm and glowing.

In addition, in vivo preclinical studies have shown favourable effects of the Kleresca® technology including stimulation of human fibroblast proliferation and increased collagen deposition. In *in vitro* studies, a significant upregulation of up to 400% of collagen production has been seen applying the Kleresca® FLE platform to human fibroblasts[5], which has furthermore been confirmed from biopsies taken during a clinical trial[8].



Before

After

Reducing fine lines



Before



After

Reducing pore size



Before



After

Inducing collagen production

Individual results may vary

Before and after invasive treatments

Invasive skin treatments are known for delivering good results, but they can have adverse side effects such as erythema, scaling of the skin, pain and swelling. Some of them lead to long downtimes for the patient[29-31].

The Kleresca® FLE technology treatment can be combined with lasers and other invasive therapies because of its anti-inflammatory effects which can normalise the skin as well as induce collagen build-up[28].

The treatment has a repairing effect at the cellular level due to the activation of the deeper layers of the skin[5,28]. This effect continues over time allowing patients to experience continuous improvements, even after the treatment has ended[6-8].

Kleresca® Pre-Post Treatment can be used in conjunction with other non-invasive or invasive techniques, to provide an optimal outcome for the patient[28]. The treatment helps to normalise and smoothen the treated skin due to the collagen build-up, anti-inflammatory effect and normalisation and de-stressing of the skin[28].

Kleresca® Pre-Post Treatment prepares and repairs the skin from within, activating skin cells prior to other skin procedures and reducing inflammation, redness and healing time.

SKIN REJUVENATION

- Induces collagen production up to 400%
- Slows down signs of skin ageing
- Improves pore size, fine lines and skin texture

Treatment mode: **Rejuvenation**

ROSACEA TREATMENT

- Treats redness, flushing and pimples
- Reduces burning and stinging sensations
- Fast results

Treatment mode: **Rejuvenation**

KLERESCA® FLE

- Stimulates the skin's own repair mechanisms
- Effective for inflammatory and aesthetic conditions
- Non-destructive, non-systemic and painless

Suitable all year round, including summer

ACNE TREATMENT

- Treats both active acne and acne scarring
- Normalises the skin
- Non-systemic, lasting up to a year and above

Treatment mode: **Therapeutic**

PRE-POST TREATMENT

- Prepares and repairs the skin from within
- Activates skin cells prior to other skin procedures
- Reduces inflammation, redness and healing time

Treatment mode: **Rejuvenation**

About Kleresca

At Kleresca, we aspire to change the fundamentals of dermatology. Our innovative technology represents a unique mode of action that allows us to create a new gold standard within the industry for the benefit of patients worldwide.

Demonstrating high safety and efficacy, the Kleresca® platform offers non-invasive treatments for both inflammatory and aesthetic conditions using fluorescent light energy (FLE) to stimulate the skin's own repair systems in a harmless, non-destructive and painless manner.

Building on the scientific heritage from LEO Pharma and KLOX Technologies, Kleresca is currently exploring the use of FLE with a view to developing more non-invasive treatments for a number of skin conditions.

10 Countries
And expanding

40+ Employees
Around the world

390+ Partner clinics
Worldwide

10,500+ Patients
And helping more every day

We are currently involved in scientific partnerships with five universities in Europe, three research centres and approximately 20 clinics to investigate the potential of FLE within present and future therapeutic areas.

We employ a laboratory team researching the impact of FLE on the skin's macrophages and in collaboration with selected research partners, Kleresca has applied for a Multidisciplinary Research Grant with the Danish Innovation Fund in order to further explore the potential of FLE in inflammatory skin diseases.

Attending a number of international congresses and conferences every year, Kleresca is becoming increasingly known in the medical and scientific environment in Europe and other parts of the world. We enjoy the attention of both scientists and clinicians due to the innovative nature of our technology.

Kleresca is also registered as FB Dermatology.

KØBENHAVNS UNIVERSITET · HEINRICH HEINE UNIVERSITÄT DÜSSELDORF · Università di Roma Tor Vergata · DTU Technical University of Denmark · UNIMORE UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA

1 kit for 1 session

Kleresca® Acne Treatment

Kleresca® Skin Rejuvenation

Kleresca® Light

Kleresca® Rosacea Treatment

Kleresca® Pre-Post Treatment

Product Name	Ship Case
Kleresca® Light	1 floor-standing lamp
Kleresca® Acne Treatment	12 kits per pack
Kleresca® Skin Rejuvenation	
Kleresca® Rosacea Treatment	
Kleresca® Pre-Post Treatment	
Operator Goggles	5 pairs per pack
Reusable Patient Goggles	1 pair per pack
Single Use Patient Eye Patches	50 pairs per pack

For further product information, please contact:
info@kleresca.com

For scientific and medical support, please contact:
medical@kleresca.com

Kleresca®

Helping people feel good about their skin

INSPIRED BY
PHOTOSYNTHESIS

WORKS AT
CELLULAR LEVEL

Legal Manufacturer:
FB Dermatology Limited / Kleresca
51 Bracken Road, Sandyford Industrial Estate, Dublin 18, Ireland

REFERENCES: 1. Freitas, L. F. de & Hamblin, M. R. IEEE J Sel Top Quantum Electron 22, (2016). **2.** Barolet, D. Semin. Cutan. Med. Surg. 27, 227–238 (2008). **3.** Opel, D. R. *et al.* J. Clin. Aesthet. Dermatol. 8, 36–44 (2015). **4.** Wang, Y. *et al.* Sci. Rep. 6, 33719 (2016). **5.** Edge, D. *et al.* J Clin Aesthet Dermatol (2019);12(5):E61–E68. **6.** Antoniou, C. *et al.* Int. J. Dermatol. 55, 1321–1328 (2016). **7.** Nikolis, A. *et al.* Int J Dermatol. 57(1):94-103 (2018) **8.** Nikolis, A. *et al.* Clin. Cosmet. Investig. Dermatol. 9, 115–125 (2016) **9.** Mahendran, A. et l. Phottodermatol Photoimmuno Photomed, 1-3 (2018) **10.** Ashkenazi, H. et l. FEMS Immunol. Med. Microbiol. 35, 17–24 (2003). **11.** Borelli, C. *et al.* Acta Derm. Venereol. 86, 316–319 (2006). **12.** Elman, M. & Lebzelter, J. Dermatol. Surg. 30, 139–146 (2004). **13.** Goldberg, D. J. & Russell, B. J. Cosmet. Laser Ther. 8, 71–75 (2006). **14.** Papageorgiou, P. *et al.* Br. J. Dermatol. 142, 973–978 (2000). **15.** Chang, S. E. *et al.* Dermatologic Surg. 33, 676–679 (2007). **16.** Sanclemente, G. *et al.* J. Eur. Acad. Dermatology Venereol. 25, 49–58 (2011). **17.** Barolet, D. *et al.* J. Invest. Dermatol. 129, 2751–9 (2009). **18.** Dungel, P. *et al.* Lasers Surg. Med. 46, 773–780 (2014). **19.** Braun, S. A. & Gerber, P. A. Int. J. Dermatol. 1–2 (2017) **20.** Sannino, M. *et al.* Clin Case Rep; 00:1-6 (2018) **21.** Mignon, C. *et al.* Sci. Rep. 7, 1–14 (2017). **22.** Nikolis, A. *et al.* Chronic Wound Care Manag. Res. 3, 101–111 (2016). **23.** Rohringer, S. *et al.* Sci. Rep. 7, 1–11 (2017). **24.** Avci, P. *et al.* Semin. Cutan. Med. Surg. 32, 41–52 (2013). **25.** Hamblin, M. R. & Demidova, T. N. Proc SPIE 6140, 1–12 (2006). **26.** Zuuren, E. *et al.* Cochrane Database Syst. Rev. (2015). **27.** Jalili, A. J Ästhet Chir. 2018. Early online 20 February. **28.** Scarcella *et al.* Clinical Case Reports 00:13 (2018). **29.** Alexiades-Armenakas MR *et al.* J Am Acad Dermatol. 58(5):719-37 (2008). **30.** Goel, A. *et al.*. Indian J Dermatol Venereol Leprol;77(3):369-379 (2011). **31.** Raulin C., *et al.* Lasers Surg Med.;32(2):78-87 (2003). **32.** Jagdeo J *et al.* Lasers Surg Med. January 22, (2018). **31.** Chung H *et al.* Ann Biomed Eng.; 40(2): 516–533 32 (2012). **32.** Hamblin MR & Hamblin M. AIMS Biophys.;4(3):337-361 (2017). **33.** Chung JH, *et al.* J Invest Dermatol.;117(5):1218-1224 (2001). **34.** Chen AC-H *et al.* PLoS One.;6(7):e22453 (2011). **35.** Bhate, K. *et al.* Br J Dermatol. 2013; 168:474-485. **36.** Thielitz, A. *et al.* Am. J. Clin. Dermatol. 2008, 9, 369–81

Learn more at www.kleresca.com